St. Jude Medical Welcomes Landmark Stroke Data from the RESPECT Trial
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the long-term data from RESPECT, a landmark trial, during a First Report session at the 2016 Transcatheter Cardiovascular Therapeutics conference in Washington, D.C.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161101006374/en/
RESPECT, a clinical trial of nearly 1,000 patients diagnosed with patent foramen ovale (PFO), which is a small opening between the upper chambers of the heart, and cryptogenic stroke (stroke from an unknown cause), compared PFO closure to medical therapy alone. Final results demonstrated that after long-term follow-up (average of ~6 years), treatment with the St. Jude Medical AMPLATZER™ PFO Occluder was more effective than medical therapy alone in reducing the risk for recurrent ischemic stroke by 45 percent.
“The final analysis revealed that PFO closure is an effective treatment option for young and middle-aged patients with PFO and stroke from an unknown cause who face lifelong risk for another stroke,” said neurologist Dr. David E. Thaler of Tufts Medical Center in Boston and a RESPECT principal investigator. “RESPECT data also show that PFO closure with the AMPLATZER PFO Occluder is safe and has a low risk of device or procedure-related complications. The device was more effective than medication alone in preventing another stroke.”
The AMPLATZER PFO Occluder is designed to lower the risk of stroke by sealing off the hole between the left and right atria – the patent foramen ovale. Normally the foramen ovale, which is a small opening between the left and right atria, closes shortly after birth, but remains patent – or open – in approximately 25 percent of adults. Left untreated, a PFO could allow dangerous clots from the veins to pass from the right side of the heart to the left and travel up to the brain and potentially cause a stroke.
“The AMPLATZER PFO Occluder procedure is minimally invasive; it is performed without an incision while the patient is sedated but still conscious,” said Dr. John D. Carroll, director of interventional cardiology at the Cardiac and Vascular Center at the University of Colorado Hospital. “Interventional cardiologists and neurologists in major North American medical centers have worked together for more than 13 years to determine if PFO closure substantially reduces the risk of recurrent stroke; the data show it does.”
“The RESPECT trial generated more than 5,800 patient years of data and on average six years of patient follow-up,” said Dr. Mark Carlson, chief medical officer and vice president of medical affairs at St. Jude Medical. “These final long-term results are key, showing the treatment to be effective in preventing another stroke in PFO patients who are otherwise healthy.”
These final analyses presented at TCT 2016, which include additional follow-up beyond those on which FDA approval was based, support continued patient benefit over an average of approximately six years of follow-up. The AMPLATZER PFO Occluder was recently approved by the Food and Drug Administration and is the only device approved in the United States for PFO closure to reduce the risk of recurrent ischemic stroke in patients, predominantly between the ages of 18 and 60 years, who have had a cryptogenic stroke due to a presumed paradoxical embolism, as determined by a neurologist and cardiologist following an evaluation to exclude known causes of ischemic stroke.
About St. Jude Medical
St. Jude Medical is a leading global medical device manufacturer and is dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has five major areas of focus that include heart failure, atrial fibrillation, neuromodulation, traditional cardiac rhythm management, and cardiovascular. For more information, please visit sjm.com or follow us on Twitter @SJM_Media .
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the company, including potential clinical successes, reimbursement strategies, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the company’s control and the risk factors and other cautionary statements described in the company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2016 and Quarterly Report on Form 10-Q for the fiscal quarter ended July 2, 2016. The company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
ZONOVILLE-INVESTMENTS-LI19.2.2018 19:21 | pressemeddelelse
Zonoville Investments Limited Announces Agreement on Acquisition of RUSAL Shares
DIGITAL-HEALTH-TECH-SHOW19.2.2018 19:07 | pressemeddelelse
The Digital Health Technology Show: The Leading Show for Healthcare Innovation Comes to London
PSMF-SUMMIT19.2.2018 14:02 | pressemeddelelse
World Patient Safety Summit is Sold Out But Space is Available at the Breakout Sessions, Held the Day after the World Summit, at the Royal Society in London
BUSINESS-TAMPERE19.2.2018 13:43 | pressemeddelelse
Tampere Attracts AV Productions with a New Incentive
TEMPO19.2.2018 12:16 | pressemeddelelse
Tempo Grows Revenue by 38% in 2017 to $17.9 Million
MORROW-SODALI19.2.2018 11:07 | pressemeddelelse
Morrow Sodali Announces Appointment of David Shammai as Corporate Governance Director - Cross Border
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum